Pulmonary fibrosis

This phase 3 trial tests an inhaled drug called treprostinil palmitil in adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time despite standard care. Participants inhale the drug or a placebo once daily for 52 weeks. Researchers measure whe…

This study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…

This study looks at the long-term safety of a drug called admilparant in people with pulmonary fibrosis (lung scarring). About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug is safe to use over time, …

This study tests whether adding nerandomilast to the standard drug mycophenolate is safe and tolerable for people with pulmonary fibrosis (lung scarring). About 120 adults with various types of lung fibrosis will take the combination for 4 months. The main goal is to see how many…

This Phase 3 trial tests whether HSK44459 tablets can slow the decline in lung function for adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. About 378 participants will take the drug or a placebo twice daily for 52 weeks. The main goa…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study will test a new imaging agent called 68Ga-1A12, which is used in a PET scan to detect fibrosis (scarring) in organs like the lungs. The goal is to see if this scan can diagnose fibrosis earlier and more accurately than current methods, which often require invasive biop…

Researchers compare two breathing techniques added to standard medical care for people with stable pulmonary fibrosis. Forty adults with mild to moderate lung restriction join the study. One group receives a manual diaphragmatic release technique, where a therapist applies gentle…

This study tests whether adding osteopathic manipulative techniques (gentle hands-on bodywork) to standard chest physiotherapy can improve lung function and reduce shortness of breath in people with progressive pulmonary fibrosis. Fifty adults with advanced lung scarring will rec…

This study tests a lightweight, battery-powered device called MoblO2 that automatically adjusts oxygen flow to keep blood oxygen at a healthy level during exercise. It is designed for people with COPD or interstitial lung disease who need supplemental oxygen. Over two weeks, 48 p…

This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…

This study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…

This study will track 427 adults with interstitial lung disease (ILD) who need a bronchoscopy as part of their care. Researchers want to see how often complications happen within 30 days after the procedure. The goal is to better understand the risks so doctors can make safer cho…

This study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis and systemic sclerosis, as well as healthy volunteers, and compare them with standard tests and lung functi…